

## RAW SEQUENCE LISTING

**The Biotechnology Systems Branch of the Scientific and Technical  
Information Center (STIC) no errors detected.**

Application Serial Number: US/10/123,383  
Source: IFWO  
Date Processed by STIC: 12-20-04

# ***ENTERED***



IFWO

## RAW SEQUENCE LISTING

DATE: 12/20/2004

PATENT APPLICATION: US/10/723,383

TIME: 12:05:08

Input Set : A:\-29-2.app

Output Set: N:\CRF4\12202004\J723383.raw

3 <110> APPLICANT: Nasoff, Marc  
 4 Deveraux, Quinn L.  
 5 Knee, Deborah A.  
 6 Aza-Blanc, Pedro  
 7 Hampton, Garret M.  
 8 Wagner, Klaus  
 9 IRM LLC  
 11 <120> TITLE OF INVENTION: Methods and Compositions for Inducing Apoptosis in  
 12 Cancer Cells  
 14 <130> FILE REFERENCE: 021288-002920US  
 16 <140> CURRENT APPLICATION NUMBER: US 10/723,383  
 17 <141> CURRENT FILING DATE: 2003-11-25  
 19 <150> PRIOR APPLICATION NUMBER: US 60/429,842  
 20 <151> PRIOR FILING DATE: 2002-11-27  
 22 <150> PRIOR APPLICATION NUMBER: US 448,960  
 23 <151> PRIOR FILING DATE: 2003-02-21  
 25 <150> PRIOR APPLICATION NUMBER: US 60/494,714  
 26 <151> PRIOR FILING DATE: 2003-08-12  
 28 <150> PRIOR APPLICATION NUMBER: US 60/504,901  
 29 <151> PRIOR FILING DATE: 2003-09-22  
 31 <160> NUMBER OF SEQ ID NOS: 15  
 33 <170> SOFTWARE: PatentIn Ver. 2.1  
 35 <210> SEQ ID NO: 1  
 36 <211> LENGTH: 64  
 37 <212> TYPE: PRT  
 38 <213> ORGANISM: Artificial Sequence  
 40 <220> FEATURE:  
 41 <223> OTHER INFORMATION: Description of Artificial Sequence: Baculovirus  
 42 Inhibitory Repeat (BIR) region motif conserved  
 43 residue consensus sequence  
 45 <220> FEATURE:  
 46 <221> NAME/KEY: MOD\_RES  
 47 <222> LOCATION: (2)..(24)  
 48 <223> OTHER INFORMATION: Xaa = any amino acid, Xaa at positions 22-24 may  
 49 be present or absent  
 51 <220> FEATURE:  
 52 <221> NAME/KEY: MOD\_RES  
 53 <222> LOCATION: (26)..(36)  
 54 <223> OTHER INFORMATION: Xaa = any amino acid  
 56 <220> FEATURE:  
 57 <221> NAME/KEY: MOD\_RES  
 58 <222> LOCATION: (38)..(39)  
 59 <223> OTHER INFORMATION: Xaa = any amino acid

## RAW SEQUENCE LISTING

DATE: 12/20/2004

PATENT APPLICATION: US/10/723,383

TIME: 12:05:08

Input Set : A:\-29-2.app

Output Set: N:\CRF4\12202004\J723383.raw

61 &lt;220&gt; FEATURE:

62 &lt;221&gt; NAME/KEY: MOD\_RES

63 &lt;222&gt; LOCATION: (41)..(56)

64 &lt;223&gt; OTHER INFORMATION: Xaa = any amino acid

66 &lt;220&gt; FEATURE:

67 &lt;221&gt; NAME/KEY: MOD\_RES

68 &lt;222&gt; LOCATION: (58)..(63)

69 &lt;223&gt; OTHER INFORMATION: Xaa = any amino acid

71 &lt;400&gt; SEQUENCE: 1

W--&gt; 72 Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

73 1 5 10 15

75 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa

76 20 25 30

78 Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

79 35 40 45

81 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa His Xaa Xaa Xaa Xaa Xaa Xaa Cys

82 50 55 60

85 &lt;210&gt; SEQ ID NO: 2

86 &lt;211&gt; LENGTH: 359

87 &lt;212&gt; TYPE: DNA

88 &lt;213&gt; ORGANISM: Artificial Sequence

90 &lt;220&gt; FEATURE:

91 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence:anti-DR5

92 Antibody A light chain variable region

94 &lt;400&gt; SEQUENCE: 2

95 gacattgcga tgaccagtc tcacaagttc atgtccacat tagtgggaga cagggtcagc 60

96 atcacctgca aggccagtc g gatgtgaat actgctatag cctggatatca acaaaaacca 120

97 gggcaatctc ctactact gatttactgg gcatccacc ggcacactgg agtccctgat 180

98 cgcttcacag gcagtggatc tgggacagat tatactctca ccatcagcag tatggaggct 240

99 gaagatgctg ccacttatta ctgccagcag tggagtagta acccgctcac gttcggtgct 300

100 gggaccaagc tggagctgaa acgggctgat gctgcaccaa ctgtatccat cttcccacc 359

103 &lt;210&gt; SEQ ID NO: 3

104 &lt;211&gt; LENGTH: 360

105 &lt;212&gt; TYPE: DNA

106 &lt;213&gt; ORGANISM: Artificial Sequence

108 &lt;220&gt; FEATURE:

109 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence:anti-DR5

110 Antibody A heavy chain variable region

112 &lt;400&gt; SEQUENCE: 3

113 caggcaaagg tccagctgca gcagtctgga gctgagctgg tgaaaccgga ggcacagtg 60

114 aagctgtcct gcaaggcttc tggctacacc ttcactgact atactataca ctgggttaaag 120

115 cagaggtctg gacagggtct tgagtggatt ggggtggttt accctggagg tgggttatata 180

116 aaatacaatg agaaattcaa ggacagggcc acattgactg cggacaaatc ctccaacaca 240

117 gtctatatgg agcttagtcg attgacatct gaaggctctg cgggtctatt ctgtgcaaga 300

118 cacgaagagg gcatctatct tgactactgg ggccaaggca ccactctcac agtctcctca 360

121 &lt;210&gt; SEQ ID NO: 4

122 &lt;211&gt; LENGTH: 118

123 &lt;212&gt; TYPE: PRT

124 &lt;213&gt; ORGANISM: Artificial Sequence

## RAW SEQUENCE LISTING

DATE: 12/20/2004

PATENT APPLICATION: US/10/723,383

TIME: 12:05:08

Input Set : A:\-29-2.app

Output Set: N:\CRF4\12202004\J723383.raw

126 &lt;220&gt; FEATURE:

127 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence:anti-DR5

128 Antibody A heavy chain subgroup B variable region

130 &lt;400&gt; SEQUENCE: 4

131 Lys Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala

132 1 5 10 15

134 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr

135 20 25 30

137 Thr Ile His Trp Val Lys Gln Arg Ser Gly Gln Gly Leu Glu Trp Ile

138 35 40 45

140 Gly Trp Phe Tyr Pro Gly Gly Gly Tyr Ile Lys Tyr Asn Glu Lys Phe

141 50 55 60

143 Lys Asp Arg Ala Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Val Tyr

144 65 70 75 80

146 Met Glu Leu Ser Arg Leu Thr Ser Glu Gly Ser Ala Val Tyr Phe Cys

147 85 90 95

149 Ala Arg His Glu Gly Ile Tyr Phe Asp Tyr Trp Gly Gln Gly Thr

150 100 105 110

152 Thr Leu Thr Val Ser Ser

153 115

156 &lt;210&gt; SEQ ID NO: 5

157 &lt;211&gt; LENGTH: 109

158 &lt;212&gt; TYPE: PRT

159 &lt;213&gt; ORGANISM: Artificial Sequence

161 &lt;220&gt; FEATURE:

162 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence:anti-DR5

163 Antibody A kappa light chain subgroup 5 variable

164 region

166 &lt;400&gt; SEQUENCE: 5

167 Asp Ile Ala Met Thr Gln Ser His Lys Phe Met Ser Thr Leu Val Gly

168 1 5 10 15

170 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Asn Thr Ala

171 20 25 30

173 Ile Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile

174 35 40 45

176 Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly

177 50 55 60

179 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Met Glu Ala

180 65 70 75 80

182 Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu

183 85 90 95

185 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala

186 100 105

189 &lt;210&gt; SEQ ID NO: 6

190 &lt;211&gt; LENGTH: 23

191 &lt;212&gt; TYPE: DNA

192 &lt;213&gt; ORGANISM: Artificial Sequence

194 &lt;220&gt; FEATURE:

195 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence:synthetic siRNA

## RAW SEQUENCE LISTING

DATE: 12/20/2004

PATENT APPLICATION: US/10/723,383

TIME: 12:05:08

Input Set : A:\-29-2.app

Output Set: N:\CRF4\12202004\J723383.raw

196 ttds(N)19TT

198 &lt;220&gt; FEATURE:

199 &lt;221&gt; NAME/KEY: modified\_base

200 &lt;222&gt; LOCATION: (3)..(21)

201 &lt;223&gt; OTHER INFORMATION: n = any nucleotide

203 &lt;400&gt; SEQUENCE: 6

W--&gt; 204 tttnnnnnnnnn nnnnnnnnnnn ntt

23

207 &lt;210&gt; SEQ ID NO: 7

208 &lt;211&gt; LENGTH: 354

209 &lt;212&gt; TYPE: DNA

210 &lt;213&gt; ORGANISM: Artificial Sequence

212 &lt;220&gt; FEATURE:

213 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence:alternate

214 sequence for anti-DR5 Antibody A heavy chain

215 variable region

217 &lt;400&gt; SEQUENCE: 7

218 aaggtccagc tgcagcagtc tggagctgag ctggtgaaac ccggggcatc agtgaagctg 60

219 tcttgcaagg cttctggcta caccttcact gactatacta tacactgggt aaagcagagg 120

220 tctggacagg gtcttgagtg gattgggtgg ttttaccctg gaggtggtta tataaaatac 180

221 aatgagaaat tcaaggacag ggccacattg actgcggaca aatcctccaa cacagtctat 240

222 atggagctta gtcgattgac atctgaagac tctgcggtct atttctgtgc aagacacgaa 300

223 gagggcatct attttgacta ctggggccaa ggcaccactc tcacagtctc ctca 354

226 &lt;210&gt; SEQ ID NO: 8

227 &lt;211&gt; LENGTH: 118

228 &lt;212&gt; TYPE: PRT

229 &lt;213&gt; ORGANISM: Artificial Sequence

231 &lt;220&gt; FEATURE:

232 &lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence:alternate

233 sequence for anti-DR5 Antibody A heavy chain

234 variable region

236 &lt;400&gt; SEQUENCE: 8

237 Lys Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala

238 1 5 10 15

240 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr

241 20 25 30

243 Thr Ile His Trp Val Lys Gln Arg Ser Gly Gln Gly Leu Glu Trp Ile

244 35 40 45

246 Gly Trp Phe Tyr Pro Gly Gly Gly Tyr Ile Lys Tyr Asn Glu Lys Phe

247 50 55 60

249 Lys Asp Arg Ala Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Val Tyr

250 65 70 75 80

252 Met Glu Leu Ser Arg Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys

253 85 90 95

255 Ala Arg His Glu Gly Ile Tyr Phe Asp Tyr Trp Gly Gln Gly Thr

256 100 105 110

258 Thr Leu Thr Val Ser Ser

259 115

262 &lt;210&gt; SEQ ID NO: 9

263 &lt;211&gt; LENGTH: 312

## RAW SEQUENCE LISTING

DATE: 12/20/2004

PATENT APPLICATION: US/10/723,383

TIME: 12:05:08

Input Set : A:\-29-2.app

Output Set: N:\CRF4\12202004\J723383.raw

```

264 <212> TYPE: DNA
265 <213> ORGANISM: Artificial Sequence
267 <220> FEATURE:
268 <223> OTHER INFORMATION: Description of Artificial Sequence:alternate
269     sequence for anti-DR5 Antibody A light chain
270     variable region
272 <400> SEQUENCE: 9
273 gacattgtga tgaccagtc tcacaagttc atgtccacat cagtgggaga cagggtcagc 60
274 atcacctgca aggccagtc ggatgtgaat actgctatag cctgggtatca acaaaaacca 120
275 gggcaatctc ctaaactact gatttactgg gcatccaccc ggcacactgg agtccctgat 180
276 cgcttcacag gcagtggatc tgggacagat tatactctca ccatcagcag tgtgcaggct 240
277 gaagacctgg cactttatta ctgtcagcaa cattatacca ctccattcac gtteggctcg 300
278 gggacaaaagt tg                                     312
281 <210> SEQ ID NO: 10
282 <211> LENGTH: 104
283 <212> TYPE: PRT
284 <213> ORGANISM: Artificial Sequence
286 <220> FEATURE:
287 <223> OTHER INFORMATION: Description of Artificial Sequence:alternate
288     sequence for anti-DR5 Antibody A light chain
289     variable region
291 <400> SEQUENCE: 10
292 Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
293   1             5             10             15
295 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Asn Thr Ala
296   20             25             30
298 Ile Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
299   35             40             45
301 Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
302   50             55             60
304 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala
305   65             70             75             80
307 Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Phe
308   85             90             95
310 Thr Phe Gly Ser Gly Thr Lys Leu
311   100
314 <210> SEQ ID NO: 11
315 <211> LENGTH: 19
316 <212> TYPE: DNA
317 <213> ORGANISM: Artificial Sequence
319 <220> FEATURE:
320 <223> OTHER INFORMATION: Description of Artificial Sequence:siPAK1-0 siRNA
321     directed against PAK1
323 <400> SEQUENCE: 11
324 agagctgcta cagcatcaa                                     19
327 <210> SEQ ID NO: 12
328 <211> LENGTH: 19
329 <212> TYPE: RNA
330 <213> ORGANISM: Artificial Sequence

```

## RAW SEQUENCE LISTING ERROR SUMMARY

DATE: 12/20/2004

PATENT APPLICATION: US/10/723,383

TIME: 12:05:09

Input Set : A:\-29-2.app

Output Set: N:\CRF4\12202004\J723383.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. ~~2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23~~Seq#:1; Xaa Pos. ~~24,25,27,28,29,30,31,32,33,34,35,36,38,39,41,42,43,44,45~~Seq#:1; Xaa Pos. ~~46,47,48,49,50,51,52,53,54,55,56,58,59,60,61,62,63~~Seq#:6; N Pos. ~~3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21~~

**VERIFICATION SUMMARY**

PATENT APPLICATION: US/10/723,383

DATE: 12/20/2004

TIME: 12:05:09

Input Set : A:\-29-2.app

Output Set: N:\CRF4\12202004\J723383.raw

L:72 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0

M:341 Repeated in SeqNo=1

L:204 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0